ALT vs BIIB: Which Stock is Better?
Side-by-side comparison of Altimmune Inc and Biogen Inc in 2026
ALT
Altimmune Inc
$3.60
BIIB
Biogen Inc
$190.48
Key Metrics Comparison
| Metric | ALT | BIIB | Winner |
|---|---|---|---|
| Market Cap | $475.88M | $27.95B | BIIB |
| P/E Ratio | N/A | 21.40 | BIIB |
| EPS (TTM) | $N/A | $8.90 | BIIB |
| Revenue Growth | 4.2% | -0.1% | ALT |
| Gross Margin | -161929.3% | 78.9% | BIIB |
Analyze ALT
Full quant analysis
Analyze BIIB
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ALT or BIIB a better investment?
Comparing ALT and BIIB: Altimmune Inc has a market cap of $475.88M while Biogen Inc has $27.95B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ALT and BIIB?
ALT (Altimmune Inc) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ALT or BIIB?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: ALT or BIIB?
ALT has higher revenue growth at 4.2% vs -0.1% for BIIB.
Which company is more profitable: ALT or BIIB?
Biogen Inc (BIIB) has higher gross margins at 78.9% compared to -161929.3% for ALT.
Which is the larger company: ALT or BIIB?
Biogen Inc (BIIB) is larger with a market cap of $27.95B compared to $475.88M for ALT.
Should I buy ALT or BIIB in 2026?
Both ALT and BIIB have investment merit. ALT trades at $3.60 while BIIB trades at $190.48. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ALT and BIIB stock?
Key differences: Market Cap ($475.88M vs $27.95B), P/E Ratio (N/A vs 21.4x), Revenue Growth (4.2% vs -0.1%), Gross Margin (-161929.3% vs 78.9%).